Winston-Salem.

PositionTriad

WINSTON-SALEM--Targacept reported good results from clinical trials of a schizophrenia treatment. Drug giant AstraZeneca is weighing whether to exercise licensing rights for the compound, TC-5619. If it does, it will pay Targacept $30 million immediately and up to $212 million more if key...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT